Current Therapies in Primary Immune Thrombocytopenia

Abstract

Immune thrombocytopenia (ITP) has long been characterized as an autoimmune disease that exhibits antibody-mediated destruction of platelets. Many of the therapies have targeted reducing the antibody production and/or the platelet destruction process within the reticuloendothelial system, including steroids, immunoglobulin, anti-RhD immunoglobulin, splenectomy, and rituximab. Relatively new insights into the pathophysiology of this disorder have led to the introduction of new therapies, such as the use of thrombopoietic agents to enhance platelet production. This review outlines many of the most commonly used therapeutic agents for the treatment of severe thrombocytopenia associated with both newly diagnosed and chronic ITP.

2011 yılında çocukluk çağı immün trombositopenik purpura hastalığı izlem ve tedavisinde değişiklikler

“…In acute ITP , treatment options include corticosteroids, IVIG and anti-D IgG and thrombocyte suspension in conditions where bleeding can not be stopped or in case of urgent surgical intervention (1,23,38,(39)(40)(41)(42)(43)(44). In recent years, interferon, monoclonal antibodies (rituksimab) and helycobacter treatment have also been tried (38).…”

“…In recent years, interferon, monoclonal antibodies (rituksimab) and helycobacter treatment have also been tried (38). None of these treatments have been shown to prevent bleeding or prevent chronicity.…”

“…80% of the patients respond to splenectomy. The response is permanent and additional treatment is not needed at least for 5 years (1,23,38,45). Partial or transient response is present in patients without complete response (45).…”

2014 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

“…Of some continued interest, and analogous to previous years, is that (1) some articles from previous most popular award listings have appeared yet again (►Table 2), and this highlights their perpetuating interest to our readership, and (2) that many are from previous young investigator award winners (►Table 1). 12,21,24,26,52 Indeed, what I find personally gratifying is that every young investigator award winner from 2010 (as announced in 2011) 7 is listed in either ►Table 1 or ►Table 2, 12,21,26,52,60 and also that every one of these articles also appeared within last year's top 100 listing. Also interesting is that a few articles on the top 50 listing (►Table 1), included as authors, individuals who were later to be awarded a young investigator award, 10,15,20,49 including one of the winners of the current "most popular" article award.…”

2013 Eberhard F. Mammen Award Announcements

“…Also of interest is that many of the articles listed are from previous Young Investigator Award Winners. 14,21,26,28,36 In conclusion, I would like to thank not only all of the authors listed in ►Table 1, but also the contributing authors who did not manage to make the top 50 list, as well as all the guest editors of issues recently published in Seminars in Thrombosis & Hemostasis.…”